IGEN keeps up Origen court battle as Roche drops suit
This article was originally published in Clinica
Executive Summary
IGEN International has said that it will maintain its Maryland court litigation against Roche Diagnostics over breaches of the licensing agreement for IGEN's proprietary Origen diagnostic detection technology. The company confirmed it was keeping up its action just as Roche agreed to dismiss its Delaware patent suit against IGEN, and agreed to reimburse IGEN's legal fees incurred in defending the suit. These amount to some $5.7 million.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.